

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

6-AZACYTIDINE - COMPOUND WITH WIDE SPECTRUM OF ANTIVIRAL ACTIVITY

I. Alexeeva^a; N. Dyachenko^b; L. Nosach^b; V. Zhovnovataya^b; S. Rybalko^c; R. Lozitskaya^d; A. Fedchuk^e; V. Lozitsky^e; T. Gridina^e; A. Shalamay^a; L. Palchikovskaja^a; O. Povnitsa^b

^a Institute of Molecular Biology and Genetics, Kyiv, Ukraine ^b Institute of Microbiology and Virology, Ukraine ^c Institute of Epidemiology and Infectious Diseases, Kyiv, Ukraine ^d Physical-Chemical Institute, Odesa, Ukraine ^e Institute of Emerging Infectious Diseases, Odesa, Ukraine

Online publication date: 31 March 2001

To cite this Article Alexeeva, I. , Dyachenko, N. , Nosach, L. , Zhovnovataya, V. , Rybalko, S. , Lozitskaya, R. , Fedchuk, A. , Lozitsky, V. , Gridina, T. , Shalamay, A. , Palchikovskaja, L. and Povnitsa, O.(2001) '6-AZACYTIDINE - COMPOUND WITH WIDE SPECTRUM OF ANTIVIRAL ACTIVITY', *Nucleosides, Nucleotides and Nucleic Acids*, 20: 4, 1147 — 1152

To link to this Article: DOI: 10.1081/NCN-100002508

URL: <http://dx.doi.org/10.1081/NCN-100002508>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

6-AZACYTIDINE - COMPOUND WITH WIDE SPECTRUM OF ANTIVIRAL ACTIVITY

I. Alexeeva,¹ N. Dyachenko,^{2,*} L. Nosach,² V. Zhovnovataya,²
S. Rybalko,³ R. Lozitskaya,⁴ A. Fedchuk,⁵ V. Lozitsky,⁵ T. Gridina,⁵
A. Shalamay,¹ L. Palchikovskaja,¹ and O. Povnitsa²

¹Institute of Molecular Biology and Genetics, Kyiv, Ukraine

²Institute of Microbiology and Virology, Kyiv-143, Ukraine 03143

³Institute of Epidemiology and Infectious Diseases, Kyiv, Ukraine

⁴Physical-Chemical Institute, Odesa, Ukraine

⁵Institute of Emerging Infectious Diseases, Odesa, Ukraine

ABSTRACT

6-azacytidine demonstrates activity against adenoviruses types 1, 2, 5. It inhibit synthesis of viral DNA and proteins. 6-AC shows antiherpetic and antiinfluenza action during experimental infection in mice. 6-AC is prospective for drug development as an antiviral substance with a wide spectrum of activity.

INTRODUCTION

The chemotherapy of virus infections is developing rather intensively now. It is very important for medicine owing to the wide spread of influenza virus, herpes simplex virus and adenoviruses and their important role in pathology. Modified nucleosides have proven to be the useful substances for antiviral and anticancer drug design. 6-Azacytidine (2- β -D-ribofuranosyl-5-amino-1,2,4-triazin-3(2H)-on; 6-AC) is an original structural cytidine analogue (Fig. 1). The objective of the present investigation is to study of the antiviral activity 6-AC in different *in vitro* and *in vivo* models.

*Corresponding author. Fax at +38 044 266 23 79; E-mail: dyachenko@srv.imv.kiev.ua




Figure 1. 6-Azacytidine.

MATERIALS AND METHODS

The method of synthesis for 6-azacytidine, based on a simplified one-step variant of a «silyl condensation», was developed in our laboratory. Selective N₂-glycosylation of 5-amino-1,2,4-triazine-3(2H)-one (6-azacytosine) by peracetylribofuranose in the presence of hexamethyldisilazane, trimethylchlorosilane, and tin tetrachloride (catalytic) gives the tri-o-acyl derivative of 6-azacytidine in 68% yield. The subsequent unblocking of the glycon moiety in alkaline medium led to unprotected 6-AC (1). The structure of 6-AC was confirmed by their ¹H-NMR spectral data.

After crystallization from 80% ethanol 6-AC was obtained as colorless crystals, m.p. 223–225°C. UV(H₂O): λ_{max} 264 nm (lg ε 3.9). ¹H-NMR (DMSO-d₆) δ: 8.018 (s, 1H, H^a-N); 7.901 (s, 1H, H^b-N); 7.503 (s, 1H, H-C₅); 5.970 (d, 1H, H-1'); 5.191 (d, 1H, OH-2'); 4.978 (d, 1H, OH-3'); 4.680 (t, 1H, OH-5'); 4.200 (dd, 1H, H-2'); 3.950 (dd, 1H, H-3'); 3.486 (m, 1H, H^a-5'); 3.359 (m, 1H, H^b-5').

Hep-2 or HeLa cells were grown in tubes with the strips of the cover glasses. After 48 h, cells were infected with adenoviruses type 1, 2, 5 (Ad-1, Ad-2 or Ad-5), further, after 60 min adsorption of virus, cells were washed with Hanks'

Table 1. Influence of 6-AC on the Ad 2 Reproduction in Hep-2 Cell Culture

Concentration μg/ml	Inhibition of Number of Cells with Intranuclear Inclusions, %	Virus Titres lg CTD ₅₀
125	100	0
62	100	0
16	82	2.7
8	86	—
0.5	62	2.7
0 (Control)	—	4.45



Table 2. Influence of 6-AC on the Ad 5 Reproduction in Hep-2 Cell Culture

Concentration of 6-AC, $\mu\text{g/ml}$	Percent of Cells with Viral Inclusion Bodies	Inhibition of Infection, %
125	0	100
62	0	100
16	0	100
8	0	100
0.5	24	61
0 (Control)	62	

solution and incubated in Eagle medium carrying 6-AC of varying concentrations. 48 h following infection the cells were fixed, stained with 0.01% acridine orange solution and investigated by luminescent microscopy. The infected cells were revealed by presence of the virus-specific intranuclear inclusions. An inhibition of




Figure 2. The inhibitory action of 6-AC on quantity of ad-1 infected cells with intranuclear inclusion (1) and hexon antigen (2) in cell culture HeLa.

Table 3. Prevention Action of 6-AC During Experimental Herpetic Infection

Preparation	Doses mg/kg	Quantity of Mice in Experiment	Lethal Cases		MP**	IE**
			Total	%		
6-AC	0.01	14	8	57.1	1.73	42.19
	0.1	14	12	85.7	1.16	13.79
	0.5	14	10	71.4	1.40	28.57
	1.0	12	2	16.6	6.02	83.38
Acyclovir	1.0	14	4	28.5	3.50	71.14
Placebo		14	14	100		

*-Multiple of protection.

** -Index of efficiency.

virus reproduction in cell cultures by 6-AC was determined by a reduction in the number (percent) of cells with inclusions (1).

Mice infected intracerebrally with herpes simplex virus (HSV) type 1 were injected intramuscularly with 6-AC in 24 hrs before or after infection.

Influenza infection in mice (12–14 g) was modeled by intranasal challenge of A/PR/8/34 (H1N1) strain using 4 animals per each logarithmic dilution of virus containing material. 6-AC was instilled intranasally in dose 25 mg/kg per day during 5 days beginning from 24 hours before infection. The death of animals was registered during 14 days after infection.

RESULTS

6-AC over a wide range of concentrations (0,5–125 $\mu\text{g/ml}$) inhibits the synthesis of infective Ad, formation of intranuclear inclusion bodies and hexon antigen (Tables 1 and 2, Fig. 2). It also inhibits the synthesis of viral DNA and viral polypeptides (2, 3). 6-AC in some high concentrations completely caused the switch-off of adenovirus genome expression.

The selectivity index of 6-AC was 62–125 towards Ad 1 and Ad 2 and 250 towards Ad 5. 6-AC was effective on the model of herpetic meningoencephalitis

Table 4. Therapeutic Action of 6-AC During Experimental Herpetic Infection

Preparation	Doses mg/kg	Quantity of Mice in Experiment	Lethal Cases		MP	IE
			Total	%		
6-AC	0.01	14	10	71.4	1.40	28.57
	0.1	14	10	71.4	1.40	28.57
	0.5	14	4	28.5	3.50	71.40
Acyclovir	1.0	14	6	42.8	2.30	56.59
Placebo		14	14	100		




Figure 3. Efficacy of 6-AC during experimental influenza infection in mice.



in mice. It was more active than reference compound acyclovir ("KRKA", Slovenia) if preparations were used on preventive or therapeutic schemes (Tables 3 and 4).

The intranasal instillations of 6-AC decreased lethality reliably during experimental influenza infection in mice (Fig. 3). The difference between control and experimental groups was 1,0 lg LD₅₀.

So, 6-AC has a wide spectrum of antiviral activity. It is a prospective substance for drug development and for synthesis of its derivatives.

6-AC could be used as the reference antiviral preparation to be compared with its derivatives containing macrocyclic pyridinophanes [4], which are under investigation in our group through INTAS-grant 97-31528.

ACKNOWLEDGEMENTS

This study is partially supported by INTAS (Grant 97-31528, which dedicate to study of anticancer and antiviral properties of macrocyclic pyridinophanes). We are indebted to Organizing Committee of XIV International Roundtable on Nucleosides, Nucleotides and their Biological Applications for waiving of Registration Fee. Danyla Kryzhanovsky and Andrew Fedchuk are acknowledged for their technical assistance during preparation of this report.

REFERENCES

1. Alexeeva I.; Palchikovskaya L.; Shalamay A.; Nosach L.; Zhovnovataya V.; Povnitsa O.; Dyachenko N. *Acta Biochim. Polonica*, **2000**, 47, 95–101.
2. Dyachenko N.; Nosach L.; Alexeeva I.; Zhovnovataya V.; Povnitsa O.; Chernomaz A.; Shalamay A. *Acta Biochim. Polonica*, **2000**, in press.
3. Nosach L.; Butenko S.; Timofeeva M.; Dyachenko N.; Tikhomirova T.; Alekseeva I.; Chernetsky V. *Mikrobiol. Zhurnal*, **1989**, 1, 73–75 (In Ukrainian).
4. Kuzmin V.E.; Lozitsky V.P.; Kamalov R.N.; Zheltvay A.I.; Fedtchouk A.S.; Kryzhanovsky D.N., *Acta Biochimica Polonica*, Vol. 47, No. 3, **2000**, 867–875.



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Reprints Here" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

[Order now!](#)

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN100002508>